Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CCM.0b013e31817c0bff | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cannabinoid effective targeting of atherosclerotic plaquesin vivoby optimized-PLGA nanoparticles.
Colloids Surf B Biointerfaces
December 2025
Departamento de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad de Sevilla, C/ Profesor García González 2, Sevilla 41012, Spain; Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío, Avda. Manuel Siurot s/n, Sevilla 41013, Spain. Electronic a
Aim: While selective CB2 receptor agonists hold significant promise for mitigating inflammation and atherosclerosis, their poor physicochemical properties have hampered clinical translation. To overcome this, we engineered a sophisticated, nanoparticle-based delivery system designed for precise cannabinoid deposition at atheromatous plaque sites. Our approach utilized PEGylated PLGA nanoparticles (NPs), functionalized with a peptide ligand specifically targeting vascular cell adhesion molecule-1 (VCAM-1), a well-established biomarker of atherosclerotic lesions.
View Article and Find Full Text PDFPoly(Ethylene Glycol)-Modified Catalase Blocking Reactive Oxygen Species for the Treatment of Hepatic Ischemia.
Macromol Rapid Commun
September 2025
State Key Laboratory of Organic-Inorganic Composites, Beijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, P. R. China.
Hepatic ischemia-reperfusion injury (IRI) is a severe clinical condition often leading to liver dysfunction due to oxidative stress and inflammatory responses. This study investigates the therapeutic potential of polyethylene glycol (PEG)-modified catalase (CAT) in alleviating oxidative damage associated with hepatic IRI. Catalase, an enzyme that decomposes hydrogen peroxide into water and oxygen, is modified with PEG to enhance its stability, bioavailability, and to prolong its half-life in vivo.
View Article and Find Full Text PDFRational Design of Long-Circulating Bright Fluorescent Probe for In Vivo Imaging of Amyloid-β Plaques in Alzheimer's Disease.
Anal Chem
June 2025
Key Laboratory of Green Chemistry and Technology (Ministry of Education), College of Chemistry, Sichuan University, Chengdu 610064, P. R. China.
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the pathological accumulation of amyloid-β (Aβ) plaques, which serve as crucial biomarkers for disease diagnosis and therapeutic evaluation. While fluorescence imaging has emerged as a powerful technique for Aβ detection, current probes face limitations in clinical application due to insufficient photostability and short blood half-life, resulting in compromised signal-to-noise ratios (SNRs) and imaging resolution. Herein, two bright quinoxalinone-based fluorescent probes (QNO-AD-PEGs) were presented, which incorporate hydrophilic poly(ethylene glycol) (PEG) chains for enhanced biocompatibility and an Aβ-specific ,-dimethylaminophenyl recognition unit.
View Article and Find Full Text PDFReplacing PEG-Lipid with Amphiphilic Polycarbonates in mRNA-Loaded Lipid Nanoparticles: Impact of Polycarbonate Structure on Physicochemical and Transfection Properties.
Biomacromolecules
June 2025
Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), 20 Biopolis Way, #06-01 Centros, Singapore 138668, Singapore.
Since the remarkable breakthrough of COVID-19 mRNA vaccines, lipid nanoparticles (LNPs) have gained substantial attention as the most cutting-edge clinical formulations for mRNA delivery. PEGylated lipid (PEG-lipid) has been regarded as an essential constituent of LNPs that helps to prolong their systemic circulation by preventing particle aggregation in the blood and sequestration by the mononuclear phagocyte system. Herein, we synthesized a series of mRNA-loaded nanoparticles by replacing ALC-0159 (a PEG-lipid used in the Comirnaty formulation) with amphiphilic PEG-polycarbonate diblock copolymers (PC-HNPs).
View Article and Find Full Text PDFFrom Oral to Sublingual: A Redefined Avanafil Tablet with a Breakthrough in Bioavailability and First-Pass Metabolism Avoidance.
Drug Des Devel Ther
April 2025
Department of Pharmaceutics, Faculty of Pharm Saudi Arabia Acy, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.
Introduction: Avanafil (AVA) is a very efficient phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. However, it has limited bioavailability when taken orally and considerable first-pass metabolism. Enhancing its solubility and choosing an alternative delivery route may enhance its effectiveness and duration of action.
View Article and Find Full Text PDF